Evidence map›Paper›PMID 32740676›Full record

Trial reportPsychopharmacology2020

Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.

Monalisa Jena, Archana Mishra, Biswa Ranjan Mishra, Santanu Nath, Rituparna Maiti

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03304457 (Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in First Episode Untreated Schizophrenia), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03304457 phase4completednot on this map

Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in First Episode Untreated Schizophrenia: A Randomized, Open Label, Active Controlled Study

TypeinterventionalSponsorAll India Institute of Medical Sciences, BhubaneswarRan2017 to 2018Enrolled100ConditionsSchizophreniaArmsOlanzapine, Lurasidone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Monalisa JenaDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Archana MishraDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Biswa Ranjan MishraDepartment of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Santanu NathDepartment of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Rituparna MaitiDepartment of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India. pharm_rituparna@aiimsbhubaneswar.edu.in.ORCID http://orcid.org/0000-0003-4063-9178
All India Institute of Medical Sciences Bhubaneswar · INAll India Institute of Medical Sciences · IN

Funding

All-India Institute of Medical Sciences IRG
6 · The paper itself

Abstract

objectivePatients with schizophrenia are at higher risk of cardiovascular morbidity and mortality than healthy individuals. This study was conducted to compare the effect of lurasidone and olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia.

methodsThe present study was a randomized open-label, parallel design, active-controlled clinical trial. After recruitment and randomization of 101 patients, a baseline assessment was done by PANSS, SOFAS, lipid profile, fasting blood glucose, HbA

resultsThere was a significant increase in fasting blood glucose (p < 0.001), HbA

conclusionLurasidone showed a favourable effect on lipid profile and cardiovascular risk indices over olanzapine. However, long-term studies are needed to establish and generalize the findings.

trial registrationClinicalTrials.gov NCT03304457.

Indexed as

AdultAntipsychotic AgentsBlood GlucoseCardiovascular DiseasesFemaleFollow-Up StudiesHumansLipidsLurasidone HydrochlorideMaleMetabolic DiseasesMiddle AgedOlanzapineSchizophreniaTreatment OutcomeYoung AdultAntipsychotic AgentsBlood GlucoseLipidsLurasidone HydrochlorideOlanzapineAtherogenic indexCardiovascular risk indexCoronary risk indexLurasidoneOlanzapine

Identifiers

PMID32740676
OpenAlexW3046826837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.